[
 {
  "trial": "T020",
  "source": "fulltext",
  "arms": {
   "Ketamine": {
    "randomized": "165",
    "analysed": "153"
   },
   "Placebo (saline)": {
    "randomized": "165",
    "analysed": "155"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "mean": "7.5",
      "sd": "2.2",
      "n": "153"
     },
     "Placebo (saline)": {
      "mean": "8.2",
      "sd": "2.0",
      "n": "155"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 7,
    "form": "count",
    "definition": "EPDS > 9",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "events": "20",
      "n": "153"
     },
     "Placebo (saline)": {
      "events": "35",
      "n": "155"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 14,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "mean": "7.4",
      "sd": "2.0",
      "n": "153"
     },
     "Placebo (saline)": {
      "mean": "7.8",
      "sd": "2.1",
      "n": "155"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 14,
    "form": "count",
    "definition": "EPDS > 9",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "events": "18",
      "n": "153"
     },
     "Placebo (saline)": {
      "events": "26",
      "n": "155"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 30,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "mean": "7.3",
      "sd": "2.1",
      "n": "153"
     },
     "Placebo (saline)": {
      "mean": "7.5",
      "sd": "2.2",
      "n": "155"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 30,
    "form": "count",
    "definition": "EPDS > 9",
    "location": "Table 2",
    "values": {
     "Ketamine": {
      "events": "16",
      "n": "153"
     },
     "Placebo (saline)": {
      "events": "22",
      "n": "155"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS pain at 2 days",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (NRS score, wound pain)",
    "values": {
     "Ketamine": {
      "mean": "3.0",
      "sd": "0.9",
      "n": "153"
     },
     "Placebo (saline)": {
      "mean": "4.0",
      "sd": "1.0",
      "n": "155"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "time": "5 min after dosing",
    "location": "Table 3",
    "values": {
     "Ketamine": {
      "hallucination": "24",
      "dizziness": "56"
     },
     "Placebo (saline)": {
      "hallucination": "0",
      "dizziness": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "15 min after dosing",
    "location": "Table 3",
    "values": {
     "Ketamine": {
      "hallucination": "6",
      "dizziness": "34"
     },
     "Placebo (saline)": {
      "hallucination": "0",
      "dizziness": "2"
     }
    }
   },
   {
    "window": "intraoperative",
    "time": "Out of operation room (asked before leaving the operating room)",
    "location": "Table 3",
    "values": {
     "Ketamine": {
      "hallucination": "1",
      "dizziness": "2"
     },
     "Placebo (saline)": {
      "hallucination": "0",
      "dizziness": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2019-06-26",
   "end": "2019-07-15"
  },
  "registration": {
   "number": "ChiCTR1900022464",
   "date": null
  },
  "note": "The ± in Tables 1 and 2 and the Results is not defined anywhere in the source; read as mean ± SD. n in each entry is Table 2's column header (Ketamine n = 153, Saline n = 155), which matches the analysed numbers in the Results; 165 were randomized per arm (12 and 10 lost to follow-up). No baseline EPDS is reported. At each time Table 2 gives the EPDS score (mean ± SD) and the 'Occurrence of postpartum depression', defined in the Methods as an EPDS score > 9, so each time has a mean_sd and a count entry. Pain: the design lists one measure, 'NRS pain at 2 days', and Table 2 reports two NRS scores at 2 days postpartum: wound pain, entered under the design's name, and uterine contraction pain (Ketamine 3.0 ± 0.9, Saline 4.1 ± 0.9, n 153 and 155, p < .001), which is not a design measure and is not entered. Adverse events: Table 3 gives counts at three assessments during the operation (5 and 15 min after the study drug, and before leaving the operating room), not the number of participants with each event over the operation, so each assessment is its own entry, and a participant may be counted at more than one. Headache and vomiting are also in Table 3 but are not codebook categories. Spinal anaesthesia; ketamine 0.25 mg/kg or saline within 5 min after cord clamping.",
  "reason": "The coders differed only in the name of a second pain entry: both added Table 2's uterine contraction pain at 2 days postpartum beside wound pain, under different names taken from the source. The design lists one pain measure, 'NRS pain at 2 days', which both coders filled with wound pain; measure names follow the design and the codebook extracts only the measures the design lists, so the contraction-pain entry is dropped and its values (3.0 ± 0.9 vs 4.1 ± 0.9) are kept in the note. Every other value matches Tables 2 and 3 and the Results and is unchanged."
 },
 {
  "trial": "T043",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "173",
    "analysed": "159"
   },
   "Control group": {
    "randomized": "173",
    "analysed": "160"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Depression Scale (EPDS)",
    "day": 4,
    "form": "count",
    "definition": "EPDS > 9",
    "location": "Results, Primary outcome paragraph",
    "values": {
     "Esketamine group": {
      "events": "22",
      "n": "159"
     },
     "Control group": {
      "events": "37",
      "n": "160"
     }
    }
   },
   {
    "measure": "Edinburgh Depression Scale (EPDS)",
    "day": 42,
    "form": "percent",
    "definition": "EPDS > 9",
    "location": "Results, Primary outcome paragraph",
    "values": {
     "Esketamine group": {
      "percent": "17",
      "n": "159"
     },
     "Control group": {
      "percent": "25",
      "n": "160"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "form": "percent",
    "location": "Results, Primary outcome paragraph (Fig. 6)",
    "values": {
     "Esketamine group": {
      "dizziness_percent": "17.0",
      "visual_percent": "5",
      "hallucination_percent": "3.8"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-07",
   "end": "2023-09"
  },
  "registration": {
   "number": "ChiCTR2100053422",
   "date": "2021-11-20"
  },
  "note": "Randomized 173 per group is from the sample-size paragraph ('173 patients were randomly assigned to each group') and matches the Results' flow (control 173 - 9 propofol - 4 lost = 160; esketamine 173 - 8 propofol - 1 albinism - 5 lost = 159). No EPDS means and no baseline EPDS by arm are printed (Figures 2 and 3 only). Day 4: the Results text gives the counts with postpartum depression (EPDS > 9, the Methods' cutoff), the esketamine count written as the word 'Twenty-two', with 13.8% vs 23.1%; n is not printed beside them, so the analysed numbers (159, 160) are given, which the percentages match (22/159, 37/160). Day 42: only percentages are printed ('17% vs 25%', esketamine first), entered in a 'percent' form with the analysed n for the code to convert. Pain: NRS at 6, 12, 24 and 48 h is shown by arm only in Figure 4, with no printed values (text: lower with esketamine at 6, 12 and 24 h, P < 0.05; at 48 h P = 0.1730); Table 2's NRS values are by depressed vs non-depressed group, not by arm, so there is no pain entry. Adverse events: the Results print only the esketamine group's percentages (dizziness 17.0%, blurred vision 5%, 'illusion' 3.8%, drowsiness 3.8%), with no counts and no control values (Figure 6 prints none); they are entered in a 'percent' form with a _percent suffix, so no count field holds a percentage. 'Illusion' is entered as hallucination (the Methods list hallucination among the recorded adverse reactions); drowsiness is not a codebook category. The time of adverse-event recording is not stated, so the window is 'overall'. Enrollment is as the Results state it ('From July 2020 to September 2023', which includes follow-up); the Methods say the study ran from July 1, 2020 to July 21, 2023, with the last follow-up on September 1, 2023. The registration (printed 20/11/2021) postdates the start of the study. Anaesthesiologists could not be blinded because of esketamine's side effects; parturients and the follow-up investigator were. Esketamine 0.2 mg/kg or saline pumped over 40 min from the start of the operation, under combined spinal-epidural anaesthesia.",
  "reason": "Two differences. Adverse events: coder A put the printed percentages, with % signs, in the count fields, and coder B put them in explicitly named _percent fields under a 'percent' form; the Results print only esketamine-group percentages and no counts, so coder B's form is kept and no count field holds a percentage. Depression n: coder A left n out of the day-4 count and day-42 percent entries, and coder B gave the analysed 159 and 160; the source prints these as the analysis population and the printed percentages match them exactly (22/159 = 13.8%, 37/160 = 23.1%), and a count or percentage needs its denominator, so coder B's n is kept."
 },
 {
  "trial": "T075",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "68",
    "analysed": "68"
   },
   "Normal saline control group": {
    "randomized": "68",
    "analysed": "68"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (HADS-D score, median (IQR), preoperative)",
    "values": {
     "Esketamine group": {
      "median": "6",
      "q1": "5",
      "q3": "7",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "6",
      "q1": "5",
      "q3": "7",
      "n": "68"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (HADS-D score, median (IQR), POD1)",
    "values": {
     "Esketamine group": {
      "median": "4",
      "q1": "3",
      "q3": "5",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "5",
      "q1": "4",
      "q3": "6",
      "n": "68"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3 (HADS-D score, median (IQR), POD3)",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "68"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "moderate-to-severe pain (NRS >= 4 on coughing) on POD1",
    "day": 1,
    "form": "count",
    "definition": "NRS ≥ 4 during coughing",
    "location": "Table 3 (Primary outcome); also Results text",
    "values": {
     "Esketamine group": {
      "events": "35",
      "n": "68"
     },
     "Normal saline control group": {
      "events": "47",
      "n": "68"
     }
    }
   },
   {
    "measure": "NRS at rest (4 h, 8 h, POD1, POD3)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (NRS pain score at rest, POD1)",
    "values": {
     "Esketamine group": {
      "median": "2",
      "q1": "2",
      "q3": "4",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "3",
      "q1": "2",
      "q3": "4",
      "n": "68"
     }
    }
   },
   {
    "measure": "NRS at rest (4 h, 8 h, POD1, POD3)",
    "day": 1,
    "form": "mean_se",
    "location": "Table 5 (GEE estimated marginal means, at rest, Postop 1 d)",
    "values": {
     "Esketamine group": {
      "mean": "2.35",
      "se": "0.181",
      "lower": "2.00",
      "upper": "2.71",
      "level": "0.95",
      "n": "68"
     },
     "Normal saline control group": {
      "mean": "3.54",
      "se": "0.221",
      "lower": "3.11",
      "upper": "3.98",
      "level": "0.95",
      "n": "68"
     }
    }
   },
   {
    "measure": "NRS during coughing (4 h, 8 h, POD1, POD3)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (NRS pain score during coughing, POD1)",
    "values": {
     "Esketamine group": {
      "median": "3",
      "q1": "3",
      "q3": "5",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "4",
      "q1": "3",
      "q3": "6",
      "n": "68"
     }
    }
   },
   {
    "measure": "NRS during coughing (4 h, 8 h, POD1, POD3)",
    "day": 1,
    "form": "mean_se",
    "location": "Table 5 (GEE estimated marginal means, during coughing, Postop 1 d)",
    "values": {
     "Esketamine group": {
      "mean": "3.41",
      "se": "0.172",
      "lower": "3.08",
      "upper": "3.75",
      "level": "0.95",
      "n": "68"
     },
     "Normal saline control group": {
      "mean": "4.79",
      "se": "0.234",
      "lower": "4.34",
      "upper": "5.25",
      "level": "0.95",
      "n": "68"
     }
    }
   },
   {
    "measure": "PCIA volume and hydromorphone consumed",
    "day": 2,
    "form": "median_iqr",
    "unit": "mg hydromorphone",
    "location": "Table 3 (PCIA utilization, Hydromorphone, mg)",
    "values": {
     "Esketamine group": {
      "median": "6.96",
      "q1": "6.24",
      "q3": "7.36",
      "n": "68"
     },
     "Normal saline control group": {
      "median": "7.44",
      "q1": "6.74",
      "q3": "7.82",
      "n": "68"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 9",
    "values": {
     "Esketamine group": {
      "hallucination": "2",
      "nightmare": "6"
     },
     "Normal saline control group": {
      "hallucination": "1",
      "nightmare": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2500098525",
   "date": "2025-03-10"
  },
  "note": "136 were randomized 1:1 with no withdrawals or protocol deviations; the intention-to-treat analysis includes all 136, and every table header prints n = 68 per arm, so randomized and analysed are both 68. Tables list Control first, Esketamine second. HADS-D is median (IQR); the baseline is Table 1's preoperative value (patients were screened the day before surgery), entered as day -1. Table 3's median differences are printed positive (control minus esketamine) while the text gives them negative; per-arm medians are entered, so there are no difference entries. Pain: POD1 is day 1; the 4 h, 8 h and POD3 values fall outside the day 1 and day 2 windows and are left out. The primary outcome is defined in the Methods as NRS ≥ 4 during coughing on POD1; the Results text says 'within 24 hours' (35/68 vs 47/68, RR 0.75, 95% CI 0.56-0.99). POD1 pain is printed in two forms, medians (IQR) in Table 3 and GEE estimated marginal means with SE and 95% CI in Table 5 (model-based, 'Postop 1 d'); both are entered, the mean_se entries carrying the printed CI bounds as extra fields. Table 5 prints no n; the GEE model used the same POD1 assessments of all 68 per arm that Table 3 reports, so n is 68. Opioid: Table 3 gives total PCIA use with no time stated; the pump ran a background infusion for 48 hours, so it is entered at day 2 as an inference. Hydromorphone (mg) is entered; the PCIA volume (mL) is the same consumption in volume, 87 (78-92) esketamine vs 93 (84.25-97.75) control (8 mg hydromorphone per 100 mL). Intraoperative remifentanil (1.2 [0.9-1.7] vs 1.45 [1.1-1.9] mg) and sufentanil (40 [40-50] vs 45 [40-50] µg) are day 0 and left out. Adverse events (Table 9, postoperative): also 'Confusion and disorientation', 2 esketamine vs 3 control (not dissociation as the codebook defines it), delirium by 3D-CAM on POD1-3, 6 vs 7 (not the emergence excitement the codebook counts as agitation), and nausea and vomiting, 11 vs 21; none is entered. No enrollment period is stated; the registration date is from the Methods. Esketamine 0.25 mg/kg bolus after induction, then 0.25 mg/kg/h, stopped 15 min before the end of surgery; general anaesthesia (propofol, remifentanil).",
  "reason": "The coders differed only on Table 5's GEE estimated marginal means for POD1 pain at rest and on coughing: coder B also entered the printed 95% CIs (rest 2.00-2.71 vs 3.11-3.98; coughing 3.08-3.75 vs 4.34-5.25) and n = 68, and both match Table 5 as printed. Table 5 prints no n, but the analysis is intention-to-treat with no withdrawals and Table 3 prints n = 68 per arm for the same POD1 assessments, so n is kept (without it the SE cannot be turned into an SD). Coder B's entries are kept; everything else is the same in both coders and matches Tables 1, 3, 5 and 9."
 },
 {
  "trial": "T088",
  "source": "fulltext",
  "arms": {
   "Group A": {
    "randomized": "65",
    "analysed": "62"
   },
   "Group B": {
    "randomized": "65",
    "analysed": "62"
   },
   "Group C": {
    "randomized": "64",
    "analysed": "62"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T1, preoperative day 1)",
    "values": {
     "Group A": {
      "mean": "6.94",
      "sd": "3.535",
      "n": "62"
     },
     "Group C": {
      "mean": "5.94",
      "sd": "3.038",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 3,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T2, postoperative day 3)",
    "values": {
     "Group B": {
      "mean": "4.37",
      "sd": "3.370",
      "n": "62"
     },
     "Group C": {
      "mean": "5.58",
      "sd": "3.028",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 5,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T3, postoperative day 5) for groups B and C; third paragraph (MCID comparison) for group A's mean",
    "values": {
     "Group A": {
      "mean": "3.37",
      "n": "62"
     },
     "Group B": {
      "mean": "3.51",
      "sd": "2.248",
      "n": "62"
     },
     "Group C": {
      "mean": "4.86",
      "sd": "2.631",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 7,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T4, postoperative day 7) for group B; third paragraph (MCID comparison) for the means of groups A and C",
    "values": {
     "Group A": {
      "mean": "2.35",
      "n": "62"
     },
     "Group B": {
      "mean": "3.00",
      "sd": "1.311",
      "n": "62"
     },
     "Group C": {
      "mean": "4.18",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 14,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T5, postoperative day 14) for groups A and B; third paragraph (MCID comparison) for group C's mean",
    "values": {
     "Group A": {
      "mean": "1.88",
      "sd": "1.796",
      "n": "62"
     },
     "Group B": {
      "mean": "2.76",
      "sd": "1.159",
      "n": "62"
     },
     "Group C": {
      "mean": "3.17",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 30,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T6, postoperative day 30)",
    "values": {
     "Group A": {
      "mean": "1.57",
      "sd": "1.565",
      "n": "62"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 42,
    "form": "mean_sd",
    "location": "Discussion, second paragraph (T7, postoperative day 42)",
    "values": {
     "Group A": {
      "mean": "1.33",
      "sd": "1.381",
      "n": "62"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "form": "percent",
    "location": "Results, Comparison of adverse events (Table 4 not in the source text); also Discussion",
    "values": {
     "Group A": {
      "any_ae_percent": "69.4"
     },
     "Group B": {
      "any_ae_percent": "30.6"
     },
     "Group C": {
      "any_ae_percent": "3.2"
     }
    }
   },
   {
    "window": "overall",
    "location": "Discussion (side-effects paragraph)",
    "values": {
     "Group B": {
      "psychiatric_any": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-02-03",
   "end": "2024-05-05"
  },
  "registration": {
   "number": "ChiCTR2400080617",
   "date": "2024-02-02"
  },
  "note": "Tables 1-4 are not in the source (captions with 'Download CSV / Display Table' only), and Figure 3 (adjusted EPDS means with SE bars) prints no values, so every EPDS value comes from the Discussion. Its second paragraph gives 'mean ± x' for single arm-times (T1 = preoperative day 1, entered as day -1; T2-T7 = postoperative days 3, 5, 7, 14, 30 and 42); the ± is not labelled and is read as SD, since as SEs with n = 62 these values would imply SDs beyond the 0-30 scale. Its third (MCID) paragraph prints means inside subtractions, with no SD: day 5 '4.86–3.37' (C, A), day 7 '4.18–2.35' (C, A) and '4.18–3.00' (C, B), day 14 '3.17–1.88' (C, A) and '2.76–1.88' (B, A); the arms follow from the comparison each names and from the second paragraph's values, and these arm-times carry a mean with no sd. Not printed: group B at baseline, 30 and 42 days; group A at day 3; group C at 30 and 42 days. Whether the means are raw or model-adjusted is not stated. Randomized 65, 65 and 64 with 3, 2 and 3 dropouts, yet the Results say the final analysis included 186 patients, 62 per group (65 - 2 = 63 and 64 - 3 = 61 do not match 62); analysed and each entry's n are recorded as printed, 62, since dropouts were removed for incomplete outcome assessments and no n is printed per time. The Discussion also gives Cohen's d (mean difference / pooled SD) for A vs C at days 5, 7 and 14 (0.58, 0.82, 0.70) and for A vs B at day 14 (0.58); these are not entered, since the arms' means are printed and the codebook's difference form is for sources that give only a mean difference, odds ratio or risk ratio. No counts by EPDS cutoff are printed by arm. Pain: VAS at 4, 12, 24 and 48 h and PCIA bolus times are only in Table 3, which is not available; the text says VAS was higher in group A than C at 4 h (p < 0.01), with no differences at 12, 24 or 48 h, and no rescue analgesia was needed. Adverse events: only the percentage of each group with any adverse event is printed (A 69.4%, B 30.6%, C 3.2%), entered in a 'percent' form with a _percent suffix rather than as counts; Table 4's individual events (blurred vision, dizziness, drowsiness, nausea and vomiting, increased secretions, diplopia, hallucinations, hypertension, facial flushing) are not available. The Discussion says one patient in group B had transient psychiatric symptoms after administration, resolved with propofol 1 mg/kg (psychiatric_any 1 for group B only; the other groups are not stated). All side effects occurred during surgery or in the recovery room. Groups A and B both received esketamine 0.25 mg/kg after cord clamping; group A also had esketamine 1 mg/kg in the 48-h PCIA. Combined spinal-epidural anaesthesia. Enrollment is the Results' screening period; registration is 'Date of first registration: February 2nd, 2024'.",
  "reason": "Adverse events: only percentages with any adverse event are printed, so coder B's 'percent' form with _percent fields is kept over coder A's percentages with % signs in count fields; group B's one patient with psychiatric symptoms stays a count in its own entry. n: none is printed per time, but the analysis included 62 per group after removing patients with incomplete assessments, so coder B's n = 62 is kept, with the source's inconsistent dropout arithmetic noted. Means printed without an SD (MCID paragraph) carry no sd field, as coder A gave them, rather than coder B's null. Coder B's Cohen's d entries are dropped: the arms' means are printed, and the codebook's difference form is for sources giving only the difference and has no standardized scale; the d values stay in the note."
 },
 {
  "trial": "T097",
  "source": "fulltext",
  "arms": {
   "Post-ESK group": {
    "randomized": "40",
    "analysed": "37"
   },
   "Pre-ESK group": {
    "randomized": "40",
    "analysed": "40"
   },
   "Placebo group": {
    "randomized": "40",
    "analysed": "36"
   }
  },
  "depression": [
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 2 (Preoperative)",
    "values": {
     "Post-ESK group": {
      "mean": "3.3",
      "sd": "1.3",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "3.4",
      "sd": "1.8",
      "n": "40"
     },
     "Placebo group": {
      "mean": "3.3",
      "sd": "1.6",
      "n": "36"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "count",
    "definition": "PHQ-9 > 9",
    "location": "Table 3 (Preoperative)",
    "values": {
     "Post-ESK group": {
      "events": "0",
      "n": "37",
      "bands": {
       "0–4": "30",
       "5–9": "7",
       "> 9": "0"
      }
     },
     "Pre-ESK group": {
      "events": "1",
      "n": "40",
      "bands": {
       "0–4": "33",
       "5–9": "6",
       "> 9": "1"
      }
     },
     "Placebo group": {
      "events": "0",
      "n": "36",
      "bands": {
       "0–4": "31",
       "5–9": "5",
       "> 9": "0"
      }
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2 (POD1)",
    "values": {
     "Post-ESK group": {
      "mean": "5.2",
      "sd": "2.2",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "3.9",
      "sd": "1.3",
      "n": "40"
     },
     "Placebo group": {
      "mean": "5.7",
      "sd": "3.1",
      "n": "36"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 1,
    "form": "count",
    "definition": "PHQ-9 > 9",
    "location": "Table 3 (POD1)",
    "values": {
     "Post-ESK group": {
      "events": "1",
      "n": "37",
      "bands": {
       "0–4": "15",
       "5–9": "21",
       "> 9": "1"
      }
     },
     "Pre-ESK group": {
      "events": "0",
      "n": "40",
      "bands": {
       "0–4": "28",
       "5–9": "12",
       "> 9": "0"
      }
     },
     "Placebo group": {
      "events": "5",
      "n": "36",
      "bands": {
       "0–4": "17",
       "5–9": "14",
       "> 9": "5"
      }
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (POD2)",
    "values": {
     "Post-ESK group": {
      "mean": "3.1",
      "sd": "1.4",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "2.5",
      "sd": "1.7",
      "n": "40"
     },
     "Placebo group": {
      "mean": "3.4",
      "sd": "1.4",
      "n": "36"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 2,
    "form": "count",
    "definition": "PHQ-9 > 9",
    "location": "Table 3 (POD2)",
    "values": {
     "Post-ESK group": {
      "events": "0",
      "n": "37",
      "bands": {
       "0–4": "30",
       "5–9": "7",
       "> 9": "0"
      }
     },
     "Pre-ESK group": {
      "events": "0",
      "n": "40",
      "bands": {
       "0–4": "36",
       "5–9": "4",
       "> 9": "0"
      }
     },
     "Placebo group": {
      "events": "0",
      "n": "36",
      "bands": {
       "0–4": "28",
       "5–9": "8",
       "> 9": "0"
      }
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS pain score",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 5 (On POD1, VAS score)",
    "values": {
     "Post-ESK group": {
      "mean": "2.9",
      "sd": "1.4",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "2.4",
      "sd": "1.4",
      "n": "40"
     },
     "Placebo group": {
      "mean": "3.5",
      "sd": "1.8",
      "n": "36"
     }
    }
   },
   {
    "measure": "VAS pain score",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 5 (On POD2, VAS score)",
    "values": {
     "Post-ESK group": {
      "mean": "1.5",
      "sd": "0.8",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "1.1",
      "sd": "0.7",
      "n": "40"
     },
     "Placebo group": {
      "mean": "1.4",
      "sd": "0.8",
      "n": "36"
     }
    }
   },
   {
    "measure": "PCA pump presses (sufentanil/oxycodone pump)",
    "day": 1,
    "form": "mean_sd",
    "unit": "presses",
    "location": "Table 5 (On POD1, PCIA compression time)",
    "values": {
     "Post-ESK group": {
      "mean": "9.9",
      "sd": "7.9",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "7.6",
      "sd": "8.0",
      "n": "40"
     },
     "Placebo group": {
      "mean": "13.4",
      "sd": "12.1",
      "n": "36"
     }
    }
   },
   {
    "measure": "PCA pump presses (sufentanil/oxycodone pump)",
    "day": 2,
    "form": "mean_sd",
    "unit": "presses",
    "location": "Table 5 (On POD2, PCIA compression time)",
    "values": {
     "Post-ESK group": {
      "mean": "13.2",
      "sd": "9.3",
      "n": "37"
     },
     "Pre-ESK group": {
      "mean": "11.0",
      "sd": "10.8",
      "n": "40"
     },
     "Placebo group": {
      "mean": "17.4",
      "sd": "15.4",
      "n": "36"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "time": "not stated (first row of Table 7, before the POD 1 rows)",
    "location": "Table 7",
    "values": {
     "Post-ESK group": {
      "hallucination": "0"
     },
     "Pre-ESK group": {
      "hallucination": "2"
     },
     "Placebo group": {
      "hallucination": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "POD 1",
    "location": "Table 7",
    "values": {
     "Post-ESK group": {
      "dizziness": "17"
     },
     "Pre-ESK group": {
      "dizziness": "16"
     },
     "Placebo group": {
      "dizziness": "17"
     }
    }
   },
   {
    "window": "postoperative",
    "time": "POD 2",
    "location": "Table 7",
    "values": {
     "Post-ESK group": {
      "dizziness": "2"
     },
     "Pre-ESK group": {
      "dizziness": "1"
     },
     "Placebo group": {
      "dizziness": "2"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-09",
   "end": "2023-05"
  },
  "registration": {
   "number": "ChiCTR2100050874",
   "date": "2021-09-05"
  },
  "note": "120 were randomized, 40 per group (Methods). Results: 2 excluded for postoperative bleeding and fever and 5 for haemolysed blood samples; Table 1's column headers give the analysed numbers, Placebo (36), Pre-ESK (40), Post-ESK (37), used as n for every outcome (Tables 2, 3, 5 and 7 print no n; Table 3's bands add up to these numbers at each time and its percentages use them). Tables list Placebo, Pre-ESK, Post-ESK in that order; Table 2's significance superscripts are dropped. Preoperative values (the day before surgery) are entered as day -1. The Statistical analysis says continuous data are mean and SD. PHQ-9 counts: Table 3 gives bands 0-4, 5-9 and > 9 at each time; the count entries use the > 9 band as printed (definition 'PHQ-9 > 9'), and every band is kept under 'bands'. The paper calls 0-4 'no depressive symptoms', so its own 'depressive symptoms' is PHQ-9 ≥ 5 (bands 5-9 plus > 9), never printed as one number. Pain: the design's 'PCA pump presses' is entered from 'PCIA compression time' (all presses). Table 5's 'PCIA effective compression time' (valid presses, outside the lockout) is not a design measure and is not entered: POD1 Placebo 11.3 ± 8.9, Pre-ESK 6.4 ± 5.9, Post-ESK 8.6 ± 6.4; POD2 14.6 ± 11.8, 9.4 ± 8.5, 11.2 ± 7.0. Whether the POD2 press counts are cumulative or for that day alone is not stated. QoR-15 is not entered. Adverse events (Table 7, 'Postoperative complications'): hallucination has no time (its row sits above the POD 1 and POD 2 rows); dizziness is given separately on POD 1 and POD 2, and a patient may be counted on both days; nausea and vomiting are also reported but are not codebook categories. Enrollment: the Results give no dates; the Methods say the study took place between September 2021 and May 2023. The registration date, printed 05/09/2021, is read as day/month (5 September 2021), consistent with the study starting in September 2021. Esketamine 0.2 mg/kg IV within 10 min after induction (Post-ESK) or 2 h before induction (Pre-ESK); placebo saline after induction; general anaesthesia.",
  "reason": "n: coder A left n out because Tables 2, 3, 5 and 7 print none; coder B used Table 1's analysed numbers (36, 40, 37), and Table 3's bands sum to exactly these at every time, so coder B's n is kept. Bands: coder B also kept all of Table 3's PHQ-9 bands beside the '> 9' count both coders entered; they are printed counts and the only way to reach the paper's own threshold for depressive symptoms (PHQ-9 ≥ 5) without computing, so they stay. Measure name: both coders added Table 5's 'PCIA effective compression time' (valid presses) under different source-derived names; it is not a design measure (the design's 'PCA pump presses' is the all-presses row), so it is dropped and its values are kept in the note."
 }
]